Market Overview:
The global solid tumor drug market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, technological advancements in the field of oncology, and rising demand for targeted therapies. The small molecules segment is expected to dominate the global solid tumor drug market during the forecast period. This segment is anticipated to grow at a CAGR of 11% from 2018 to 2030. The biologics segment is projected to grow at a CAGR of 9% during the same period. Oncology was the largest application segment in 2017 and it is estimated that this trend will continue during the forecast period as well.
Product Definition:
Solid tumor drug is a type of medication used to treat cancer. It is designed to specifically target tumors that have grown from solid tissues, such as cancers of the breast, prostate, lung, and colon. Compared to traditional chemotherapy drugs, which can also be effective against solid tumors but are also highly toxic and can cause significant side effects, solid tumor drugs are generally much more targeted and specific in their action. This makes them potentially safer and more effective treatments for certain cancers.
Small Molecules:
Small molecules are the chemical compounds that have a molecular weight less than 1000. They can be administered in smaller doses and therefore have better therapeutic value compared to larger molecules. Small molecule drugs include all the prescription and over-the-counter medicines, dietary supplements, nutraceuticals (healthcare products), and recreational drugs.
Biologics:
Biologics are living organisms or products derived from living organisms and used to treat diseases. Biologics can be divided into two categories, namely therapeutic biologics and diagnostic biologics. Therapeutic biologic drugs include anti-cancer drugs that help in the treatment of cancer as well as other non-cancerous diseases such as rheumatoid arthritis, multiple sclerosis, etc.
Application Insights:
The others segment dominated the global solid tumor drug market in 2017, accounting for 33.3% share of the overall revenue. The segment includes oncology, neurology and other applications. Oncology accounted for a larger share as compared to other segments owing to increasing incidence rates of cancer across the globe. According to WHO, it is estimated that globally 1 in 6 women and 1 in 5 men are likely to develop some form of cancer during their life span. Thus growing demand from oncology application is anticipated to boost growth over the forecast period (Solid Tumor Drug Market Size by Application (Oncology, Neurology), 2018).
Increasing prevalence coupled with rising awareness about early diagnosis has resulted in increased number of new diagnosed cases every year since 2000s (decade) which has further propelled growth prospects over recent years (decade).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of key players, high R&D intensity, and availability of sophisticated infrastructure for drug development. In addition, increasing government funding for cancer research is also expected to contribute toward growth over the forecast period. Asia Pacific is expected to witness lucrative growth during the forecast period owing to factors such as low cost of clinical trials and increase in investment by various governments towards R&D activities related tumor diseases. Moreover, this region has one of the largest patient pools with respect to cancer which makes it an ideal destination for outsourcing certain types or all stages clinical trials of drugs’ molecules (small molecules & biologics).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the solid tumor drug market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in 2017 in the U.S., and this number is expected to rise in future. This will create a high demand for effective and safe solid tumor drugs, which will boost the growth of this market.
- Rising prevalence of lifestyle-associated cancers: The rising prevalence of lifestyle-associated cancers such as obesity-related cancers and tobacco-related cancers is another key factor driving the growth of the solid tumor drug market. These types of cancers are becoming increasingly common due to changing lifestyles and dietary habits among people across different regions worldwide. This is resulting in an increased demand for effective treatments for these types of tumors, which will help fuel market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Solid Tumor Drug Market Research Report
By Type
Small Molecules, Biologics
By Application
Oncology, Neurology, Radiology, Others
By Companies
AstraZeneca, Biogen, Baxter, Celgene Corporation, Abbott Laboratories, Pfizer Inc, Amgen Limited & Amgen Ireland Limited, Bristol-Myers Squibb Company, GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Johnson & Johnson
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Solid Tumor Drug Market Report Segments:
The global Solid Tumor Drug market is segmented on the basis of:
Types
Small Molecules, Biologics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Neurology, Radiology, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Biogen
- Baxter
- Celgene Corporation
- Abbott Laboratories
- Pfizer Inc
- Amgen Limited & Amgen Ireland Limited
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc.
- F. Hoffmann-La Roche Ltd.
- Eli Lilly and Company
- Johnson & Johnson
Highlights of The Solid Tumor Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Small Molecules
- Biologics
- By Application:
- Oncology
- Neurology
- Radiology
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Solid Tumor Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Solid tumor drugs are medications that are used to treat cancer. These drugs work by stopping the growth of tumors.
Some of the major companies in the solid tumor drug market are AstraZeneca, Biogen, Baxter, Celgene Corporation, Abbott Laboratories, Pfizer Inc, Amgen Limited & Amgen Ireland Limited, Bristol-Myers Squibb Company, GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Johnson & Johnson.
The solid tumor drug market is expected to grow at a compound annual growth rate of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Solid Tumor Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Solid Tumor Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Solid Tumor Drug Market - Supply Chain
4.5. Global Solid Tumor Drug Market Forecast
4.5.1. Solid Tumor Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Solid Tumor Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Solid Tumor Drug Market Absolute $ Opportunity
5. Global Solid Tumor Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Solid Tumor Drug Market Size and Volume Forecast by Type
5.3.1. Small Molecules
5.3.2. Biologics
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Solid Tumor Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Solid Tumor Drug Market Size and Volume Forecast by Application
6.3.1. Oncology
6.3.2. Neurology
6.3.3. Radiology
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Solid Tumor Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Solid Tumor Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Solid Tumor Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Solid Tumor Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Solid Tumor Drug Demand Share Forecast, 2019-2026
9. North America Solid Tumor Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Solid Tumor Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Solid Tumor Drug Market Size and Volume Forecast by Application
9.4.1. Oncology
9.4.2. Neurology
9.4.3. Radiology
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Solid Tumor Drug Market Size and Volume Forecast by Type
9.7.1. Small Molecules
9.7.2. Biologics
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Solid Tumor Drug Demand Share Forecast, 2019-2026
10. Latin America Solid Tumor Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Solid Tumor Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Solid Tumor Drug Market Size and Volume Forecast by Application
10.4.1. Oncology
10.4.2. Neurology
10.4.3. Radiology
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Solid Tumor Drug Market Size and Volume Forecast by Type
10.7.1. Small Molecules
10.7.2. Biologics
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Solid Tumor Drug Demand Share Forecast, 2019-2026
11. Europe Solid Tumor Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Solid Tumor Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Solid Tumor Drug Market Size and Volume Forecast by Application
11.4.1. Oncology
11.4.2. Neurology
11.4.3. Radiology
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Solid Tumor Drug Market Size and Volume Forecast by Type
11.7.1. Small Molecules
11.7.2. Biologics
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. ByCountry
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Solid Tumor Drug Demand Share, 2019-2026
12. Asia Pacific Solid Tumor Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Solid Tumor Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Solid Tumor Drug Market Size and Volume Forecast by Application
12.4.1. Oncology
12.4.2. Neurology
12.4.3. Radiology
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Solid Tumor Drug Market Size and Volume Forecast by Type
12.7.1. Small Molecules
12.7.2. Biologics
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Solid Tumor Drug Demand Share, 2019-2026
13. Middle East & Africa Solid Tumor Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Solid Tumor Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Solid Tumor Drug Market Size and Volume Forecast by Application
13.4.1. Oncology
13.4.2. Neurology
13.4.3. Radiology
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Solid Tumor Drug Market Size and Volume Forecast by Type
13.7.1. Small Molecules
13.7.2. Biologics
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Solid Tumor Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Solid Tumor Drug Market: Market Share Analysis
14.2. Solid Tumor Drug Distributors and Customers
14.3. Solid Tumor Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AstraZeneca
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Biogen
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Baxter
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Celgene Corporation
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Abbott Laboratories
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pfizer Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Amgen Limited & Amgen Ireland Limited
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bristol-Myers Squibb Company
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. GlaxoSmithKline plc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. F. Hoffmann-La Roche Ltd.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Eli Lilly and Company
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Johnson & Johnson
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
